文献速递艾滋病与性传播感染

西班牙HIV感染者中晚期诊断持续存在且抗逆转录病毒治疗反应较差:移民与本土出生人群的比较

Persistence of late HIV diagnosis and poorer response to antiretrovirals: a comparison between migrants and native-born people with HIV in Spain.
PubMed 文献 · Clin Microbiol Infect · 2026-05-12

结果显示,拉丁美洲、撒哈拉以南非洲及其他地区移民的晚期诊断风险更高,且撒哈拉以南非洲移民的CD4恢复较差,部分人群病毒学抑制率较低,这些差异随时间持续存在。

要点

  • 移民在西班牙新诊断HIV中占比从2004年37.1%升至2023年59.3%,以拉丁美洲人为主。
  • 拉丁美洲、撒哈拉以南非洲及其他地区移民的晚期诊断风险显著高于本土出生者。
  • 撒哈拉以南非洲移民CD4恢复减少77.0个细胞/μL,且男性病毒学抑制率较低。

核心结论

  • 移民在西班牙新诊断HIV中占比增长,晚期诊断在撒哈拉以南非洲和拉丁美洲移民中持续更常见。
  • 尽管抗逆转录病毒治疗启动率总体相当,但按原籍地区划分的治疗反应不平等持续存在。
  • 需要更好的预防、早期诊断和关怀参与策略。

主要发现

  • 晚期诊断在拉丁美洲移民中调整OR为1.58(95%CI 1.44-1.73),撒哈拉以南非洲移民为1.43(1.24-1.64),其他地区为1.22(1.05-1.41)。
  • 男性中拉丁美洲和撒哈拉以南非洲移民晚期诊断更高;女性中仅拉丁美洲移民更高。
  • 2019-2023年拉丁美洲男性治疗启动调整OR为0.60(95%CI 0.37-0.95)。
  • 48周病毒学抑制仅在撒哈拉以南非洲男性中较低,调整OR为0.55(95%CI 0.41-0.75)。
  • CD4恢复在撒哈拉以南非洲移民中调整均值差为-77.0(95%CI -94.9至-59.1),拉丁美洲移民为-21.3(-30.6至-11.9)。

关键数值与推荐

  • 晚期诊断定义为入组时CD4<350细胞/μL或AIDS。
  • 治疗启动定义为入组后3个月内开始抗逆转录病毒治疗。
  • 病毒学抑制定义为病毒载量<50拷贝/mL。
  • CD4变化评估时间为抗逆转录病毒治疗启动后48周。

临床怎么用

  • 对来自拉丁美洲和撒哈拉以南非洲的移民应加强早期HIV检测和 linkage to care。
  • 对撒哈拉以南非洲移民需关注治疗后的免疫恢复和病毒学抑制。
  • 临床应认识到移民人群晚期诊断和治療反应差异可能持续存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Migrants living with HIV face barriers to accessing and staying in care, potentially worsening outcomes. We compared key HIV care continuum indicators by region of origin (ROI) overall/by sex and assessed whether disparities changed over time. METHODS: We included adults with HIV enrolled in the Spanish CoRIS cohort (2004-2023). Outcomes were late diagnosis (LD; CD4 <350 cells/μL or AIDS at enrolment), antiretroviral treatment (ART) initiation within 3 months of cohort entry, virological suppression (viral load <50 copies/mL), and CD4 change at 48 weeks after ART initiation. We assessed associations between ROI and outcomes using multivariable models and tested temporal trends by including region-by-calendar-period interactions. RESULTS: Among 20 215 participants, 54.1% were from Spain and 45.9% were born abroad. The proportion of people born abroad increased from 37.1% (2004) to 59.3% (2023), mainly driven by Latin Americans (LA). LD was more frequent among LA (adjusted OR [aOR] 1.58; 95% CI 1.44-1.73), Sub-Saharan Africans (SSA) (1.43; 1.24-1.64), and other regions (1.22; 1.05-1.41) compared with people born in Spain. Among men, LD was higher in LA and SSA; among women it was higher only in LA. Overall, ART initiation within 3 months did not differ, although LA men had lower odds in 2019-2023 (aOR 0.60; 0.37-0.95). Virological suppression at 48 weeks was lower only in SSA men (aOR 0.55; 0.41-0.75). CD4 recovery was reduced in SSA (adjusted mean difference -77.0; 95% CI -94.9 to -59.1) and LA (-21.3; -30.6 to -11.9). Disparities in LD and treatment-response persisted over time. CONCLUSIONS: Migrants account for a growing share of new HIV diagnoses in Spain. LD remains more common among SSA and LA, and healthcare access policy changes have not ameliorated these gaps. Although ART initiation appears comparable, inequalities in treatment-response persist by ROI. Better strategies for prevention, early diagnosis, and care engagement are needed.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Perez-Molina JA, Suárez-Robles M, Sánchez-López MB, et al. Persistence of late HIV diagnosis and poorer response to antiretrovirals: a comparison between migrants and native-born people with HIV in Spain. Clin Microbiol Infect. 2026. PMID: 42119887. doi:10.1016/j.cmi.2026.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。